The GLP-1 Moment: Why Pharmacy Just Changed

When patients walk into a pharmacy to start a GLP-1 medication, they’re usually thinking one thing: weight loss. What they should be thinking about is everything else that’s happening to their body.

Over the past eighteen months, GLP-1 medications have become mainstream. Millions of people are using semaglutide, tirzepatide, and other agents to lose weight. People are increasingly educated through social media about GLP-1 patients losing muscle mass, and rightly so. Up to 40 percent of that weight loss can be lean body mass, not fat. A 2025 study in Cell Reports Medicine demonstrated that GLP-1 recipients can experience significant lean mass loss alongside fat loss, underscoring the importance of concurrent resistance training and adequate protein intake to preserve skeletal muscle during treatment. Muscle matters. It determines your metabolic rate, your strength, your ability to age well. Lose the wrong kind of weight, and you’ve solved one problem and created another.

That’s where the Evolt 360 body composition analyzer comes into play. It’s a reliable and repeatable medical device using bioelectrical impedance analysis, backed by science and used in medicine.

Pharmacy 777 Albion Park is exploring what this looks like in practice. As part of an early collaboration with Evolt, the Evolt 360 has been integrated into their clinical environment. Here’s what that looks like: alongside their medication support, the team at Albion Park has been exploring the use of exercise referral and nutrition referral pathways for GLP-1 patients, with body composition monitoring via the Evolt 360 to track changes across the treatment period.

At regular intervals, a patient steps on the Evolt 360. The team can see exactly what’s changing. Are they losing fat or muscle? Is their visceral fat dropping? Is skeletal muscle mass stable? That data opens the conversation. It informs whether a referral to an exercise professional is warranted. It prompts a conversation with a nutrition provider. It gives the GLP-1 patient something most don’t have:visibility.

To my knowledge, very few pharmacies in Australia are approaching GLP-1 support this way. What Pharmacy 777 Albion Park is exploring is a more connected model, one where the device data supports broader conversations about a patient’s health journey, rather than the medication existing in isolation.

This matters because GLP-1 patients need this. Recent clinical evidence demonstrates that without deliberate intervention ie. resistance training, adequate protein, and monitoring muscle loss during GLP-1 therapy is real and substantial. With intervention, with visibility, with accountability, outcomes change.

Medication should never be guesswork. Neither should body composition. The Evolt 360 does something most body composition tools can’t, it translates composition data into actionable information. Based on a patient’s goal and their actual body composition, it offers suggestions that open a conversation with a qualified nutrition provider. That’s the intelligence layer that supports a more holistic approach.

What makes this collaboration interesting is the intent behind it. The team at Pharmacy 777 Albion Park recognizes that GLP-1 patients benefit from more than a dispensed medication. They’ve created space for measurement, for referral pathways, and for a more informed conversation about what’s actually happening inside the body. The Evolt 360 supports that. It’s holistic in its approach, and logical in its application.

“The model that Pharmacy 777 Albion Park has been exploring is genuinely exciting,” says Kelly Weideman, Co-Founder of Evolt. “It aligns with our philosophy of providing a holistic solution to actionable outcomes for better health and lifestyle optimization. I am excited that the Evolt 360 is being used for its intended purpose—not just as a body composition analyzer providing data, but as a full outcome-driven solution for the patient.”

GLP-1 medications demand something different from the broader health ecosystem. They demand accountability. They demand measurement. They demand a connected approach. The early results from this collaboration are promising, and the potential for what this model could look like at scale is something we are genuinely excited to explore together.

This is what the industry and patients are increasingly looking for: not just medication, but measurement, informed referral pathways, and outcomes. At Evolt, our philosophy is grounded in lifestyle and health-driven optimization, not just body composition analysis. We believe measurement is the foundation for real change. Pharmacy 777 Albion Park is helping to show what that could look like in practice, and we look forward to seeing where this collaboration leads.

References

Baar, K., Langer, H., & colleagues. (2026). Weight loss with GLP-1 medicines does not result in a disproportionate loss of muscle mass or function in obese mice and humans. Cell Reports Medicine. https://doi.org/10.1016/j.xcrm.2026.102665